New cancer drug trial launches in nigeria for untreated patients
NCT ID NCT06529523
Summary
This study is testing whether the immunotherapy drug tislelizumab is a safe and effective treatment for colorectal cancer patients in Nigeria who have not yet received any cancer treatment. The trial focuses on patients whose cancer has a specific genetic feature called mismatch repair deficiency (dMMR), which can make tumors more responsive to immunotherapy. Researchers will measure how well the drug shrinks tumors in two groups: people with cancer that has spread and people with earlier-stage rectal cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Lagos University Teaching Hospital
NOT_YET_RECRUITINGIdi Araba, Lagos, Nigeria
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
Obafemi Awolowo University Teaching Hospital
NOT_YET_RECRUITINGIle-Ife, Nigeria
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.